Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of ISIS 721744 in hereditary angioedema
NL-OMON49723Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of donidalorsen in hereditary angioedema (HAE), hereditary angioedema type I (HAE-I), Hereditary Angioedema Type 2 (HAE2) and 1 more (3 arms), sponsored by Ionis Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH)
Beyond the preview
Go deeper on NL-OMON49723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49723.